Serimmune Announces Use of Its SERA Platform in Study Designed to Identify Features of Long COVID Through Immune Profiling

GOLETA, Calif.–(BUSINESS WIRE)–Serimmune, a leader in understanding the antibody repertoire’s role in human disease, announced today the publication of a study in Nature in which their proprietary Serum Epitope Repertoire Analysis (SERA) technology platform was one of the methods used to analyze the biological processes associated with the development and…
Click here to view original post